SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

Clinical trial NCT02307162 · COMPLETED

Trial details

NCT number: NCT02307162
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Inflammatory Disorder of the Respiratory Tract Chronic Obstructive Pulmonary Disorder

Start date: 2014-12-01
Primary completion: 2015-07-01
Enrollment: 112

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.